

Genes regulating implantation and fetal development: a focus on mouse knockout models

Surendra Sharma¹, Shaun P. Murphy¹, and Eytan R. Barnea^{2,3}

¹ Departments of Pediatrics and Pathology, Women and Infants' Hospital of Rhode Island-Brown University, Providence, RI,

² SIEP, the Society for the Investigation of Early Pregnancy, Cherry Hill, NJ and ³ Department of Obstetrics, Gynecology and Reproductive Sciences, UMDNJ/Robert Wood Johnson Medical School, Camden, NJ

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Endogenous gene expression
 - 3.1. Gene expression in blastocyst implantation
 - 3.2. Gene expression (silencing) in the embryo
4. Mouse knockout models of reproductive-related genes
 - 4.1. Cytokines
 - 4.2. Cyclooxygenase-2
 - 4.3. Insulin-like growth factor system
 - 4.4. Matrix metalloproteinase system
 - 4.5. Transcription factors involved in placental development
 - 4.6. Indolamine-2,3-dioxygenase
5. Conclusions
6. Acknowledgements
7. References

1. ABSTRACT

Timely and efficient regulation of blastocyst implantation and fetal growth are essential for the successful reproduction of viviparous mammals. Disruptions in this regulation can result in a wide variety of human gestational complications including infertility, spontaneous abortion, fetal growth restriction, and premature delivery. The role of several groups of factors, including cytokines, hormones, transcription factors, extracellular proteinases, and angiogenic factors has been suggested in both implantation and regulation of fetal growth. Due to the inherent difficulties of studying implantation and fetal development in humans, much of our knowledge of the genes involved in these processes has been derived from animal models. The critical genetic loci involved in blastocyst implantation and fetal growth will be discussed with a focus on those genes with available mouse knockout models.

2. INTRODUCTION

Mammalian reproduction represents a highly orchestrated and intricate process. The spatial and temporal regulation of a fetal-maternal crosstalk is required for a successful pregnancy (1-5). After fertilization, the developing blastocyst must invade and establish itself in the maternal endometrium, from which it will eventually gain the crucial protection and nourishment required for development throughout gestation. Successful blastocyst implantation is contingent on two early and independent processes. While being transported through the fallopian tube, the embryo must undergo developmental changes, which culminate in the ability to implant and become invasive. In conjunction, and just as important, the uterine endometrium must undergo physiological and functional changes that allow it to become receptive to the implanting blastocyst. Thus, the process of blastocyst implantation requires the coordinated expression of a multitude of both

maternal and embryonic factors including cytokines, growth factors, hormones, adhesion molecules, and prostaglandins. Disruption in the regulation of this crosstalk can result in lowered fertility due to decreased implantation efficiency. Several gene products, such as interleukin-1 (IL-1) and leukemia inhibitory factor (LIF) appear very important for this process (6, 7). In addition, blastocyst implantation is likely to be influenced by embryo-regulated preimplantation programming which is likely to begin at a two cell embryo stage (8, 9).

After successful implantation, the major embryo-derived structure that regulates fetal growth is the placenta (10-13). In humans and mice, a hemochorial placenta forms (14). In this type of placenta, the placental trophoblast cells are in direct contact with the maternal blood supply. Especially in humans, the placenta is marked by a deep trophoblast invasion into the maternal endometrium. Accompanying this invasion is the lining of decidual vascular endothelial cells by invading trophoblasts. These processes establish an efficient maternal fetal vascular exchange, crucial to the nutrient needs of the fetus. Many diseases of the neonate and the adult are thought to have their origins in the placental regulation of fetal metabolism and development (15). Placentation is regulated by both embryonic and maternal tissues. As in implantation, this process requires the coordinated expression of both fetal and maternal genes. Much progress has been made into understanding the regulation of trophoblast cells differentiation, especially the many transcription factors involved. In addition, various secreted factors are also important in promoting the invasion of the trophoblast into the maternal decidua. Among these, the matrix metalloproteinases (MMPs), which are expressed by invading trophoblasts, disrupt the decidual extracellular matrix (16-18). Additionally, the tissue-inhibitors of metalloproteinases (TIMPs), which are expressed by the decidual stroma and regulate the actions of MMPs, are particularly well studied. Angiogenic factors secreted by trophoblast cells as well as uterine natural killer (uNK) cell-derived IFN- γ play an important role in remodeling the maternal decidual arteries and in establishment of an efficient fetal-maternal vascular exchange (19). In addition, uNK cell-derived IFN- γ has been suggested to limit the invasiveness of trophoblast into the deciduas (20). To maintain a pregnancy-compatible uterine milieu, IL-10, a potent anti-inflammatory cytokine produced at the fetal-maternal interface (20-27), is expressed during early and through mid-gestation (27). Along with its variety of roles in the regulation of local uterine immunity, IL-10 exerts a positive role in trophoblast survival, and regulation of placentation (Sharma S, Unpublished data).

To complement and extend this knowledge, the use of gene-ablated or knockout mice has proved to be a powerful tool furthering our understanding of gene function. To date, a wide range of knockout mice strains have been created, many with ablation of genes whose expression is associated with reproduction. However, a major concern with the interpretation of data from mouse knockout models is the phenomenon of redundancy. Lack

of a certain gene product(s) from conception is often accompanied by partially compensatory gene expression of genes whose products have related or overlapping functions, thus obscuring the phenotypic consequences of many gene knockouts. This appears especially true with respect to genes involved in implantation, placentation, and fetal growth. With rare exceptions, most gene knockout models currently available result in only subtle reproductive defects, which may only be apparent upon encounter with a second insult in the form of inflammatory signals or other stressors. Nonetheless, gene knockout mice have provided crucial insights into the functional requirements of specific genes in the genetic networks involved in reproduction. This review will attempt to provide an overview of the dynamics of gene expression found in the embryonic and maternal reproductive tissues involved in the processes of implantation and fetal development and, with focus on studies of major models of gene ablated laboratory mice.

3. DISCUSSION

3.1. Gene expression in blastocyst implantation

Initiation of successful establishment of pregnancy involves two fundamental elements, developmental changes in the embryo which prepare it for implantation and maternal recognition of pregnancy. Unless those elements are assured, maternal recognition of pregnancy will not take place and implantation can not succeed. The process of maternal recognition of pregnancy initiates shortly after fertilization and involves secretion of specific immunomodulatory factors that allow for maternal immune receptivity of pregnancy, particularly molecules such as pre-implantation factors (PIF) (8, 9, 28).

Implantation is a dynamic process where at each stage multiple processes are involved, such as adhesiveness, invasiveness, or maternal receptivity. Models that could dissect each phase and identify the governing elements would be very useful but are not currently available. It should be noted that even within the endometrium distinct regions can be identified- those that are intimately related to implantation and have different morphology and hormonal and cytokine secretion patterns than those at distant sites, as examined by endometrial microarray analysis (28), further illustrating the significance of specific embryo derived factors. Upregulation of immune-related genes IL-15 α , IL15, DAF, IDO, Lpn, NKG5, IRF-1, and NKAT2 is found in secretory versus proliferative human endometrium using RT PCR in endometrial biopsies from healthy women. These genes may be involved in uNK cells proliferation blocking their cytolytic activity, T cell inhibition, and inhibition of the classical complement pathway (29). Differences in expression patterns in human endometrium between LH+2 to LH+7 days were examined using gene arrays (30). This reveals major changes especially in the expression of PP-14 (glycodelin), (31), osteopontin (32), IGFBP-3 (33, 34), crystallin α B (35), GPx-3, claudin-4, and SLC1A1 genes. Interestingly, expression of 153 genes was found to be elevated compared to 58 genes that showed decreased expression during the endometrial implantation window.

Differential expression of genes also occurs in the decidua and chorionic villi. As examined by gene array analysis of first trimester elective abortuses (36), these studies revealed 124 genes with high expression in both decidua and villi, 49 of which are in the decidua and other 75 genes were of the chorionic villi origin. These differentially expressed genes were further grouped in categories of cell growth-related factors, hormones/cytokines, cell adhesion molecules, signal transduction molecules, apoptosis-related factors, and cytoskeleton/extracellular matrix proteins. The most relevant genes for the decidua were IGFBP-1 and 4. In the chorionic villi, 11 upregulated genes were cell growth related, others were hCG, SP-1, GH1,2, activin, inhibin hormones and LIF receptor.

Differences are also found between early and late mouse placental gene expression. Genes up-regulated in late-stage placenta reflected the transition to a specialized organ with less proliferative activity, acquisition of endocrine functions, and adapted for metabolic exchange. These gene groups were specific for growth arrest, hormones, glycoproteins, and vascular differentiation. The genes displaying decreased expression were involved in general cell metabolism. These observations illustrate the difficulty of fully understanding the significance of each individual gene contribution versus an integrated view or reproductive process.

3.2. Gene expression (silencing) in the embryo

Gene expression in the morula and blastula revealed an interesting trend. The number of genes upregulated is lower than the number down regulated. Among the upregulated genes are those known to be involved in critical regulatory processes (Mist1, Id2, Hd1, and Reuim). The downregulated genes include CREB-binding protein, Per3, zinc finger protein 217, Krox-25, and miw1 (37). This indicates that gene expression is tightly controlled, and therefore advanced differentiation of the embryo as occurs in the blastocyst stage requires greater downregulation of previously expressed genes than in less differentiated states. This pattern compares well to the placenta where in advanced gestation there is a decrease in the number of genes expressed after major differentiation to syncytiotrophoblast has already occurred (see below).

In a mouse pregnancy model, the blastocyst can continue for 2 weeks in the presence of progesterone, and can be subsequently activated with estrogen. Analysis of 20,000 genes showed that only 229 were differentially expressed. These included cell cycle, cell signaling, and energy metabolic pathways, especially heparin-binding epidermal growth factor-like moiety (38). Recently, human embryo gene profile was also examined in the first 3 days following fertilization *in vitro*. Gene expression was found to be largely downregulated, similar to the mouse. There is also evidence that the embryonic transcriptome is already established at 2 cell stage. (39). The gene expression during mouse embryo development at the post implantation E12.5 stage revealed profound differences in gene expression between the placenta and embryo (40).

These studies illustrate again that the placenta has a greater range of gene expression than the embryo which may be considered counterintuitive considering that the embryo is undergoing the establishment of major organs and other developmental functions of the developing embryo.

4. MOUSE KNOCKOUT MODELS OF REPRODUCTIVE-RELATED GENES

The vast array of genes expressed during implantation and fetal development and their spatial and temporal regulation makes dissection and significance of the function of each gene difficult. The laboratory mouse provides a valuable model for the study of the regulation of reproductive processes. Gene knockout mice can provide valuable insights into the genetic networks involved in these processes. A wide array of gene knockout mice have been created for many genes involved in reproductive processes.

4.1. Cytokines

Interleukin-1 (IL-1) has been one of the most extensively studied cytokines involved in implantation. The complete IL-1 system consists of two soluble agonists, IL-1 α and IL-1 β , a soluble antagonist, Interleukin-1 receptor antagonist (IL-1ra), as well as two membrane-bound receptors Interleukin-1 receptor type I (IL-1RtI) and type II (IL-1RtII) (41). Signaling only occurs through the IL-1RtI, while the IL-1RtII is inert and serves only to compete with IL-1RtI for IL-1 α or IL-1 β binding (42). The antagonist IL-1ra functions in preventing IL-1 α or IL-1 β signal transduction by competitive binding to IL-1RtI (43-46). The expression of IL-1 β , IL-1ra, and IL-1RtI has been found in preimplantation embryos and maternal endometrial epithelium of both humans and mice (47-56).

Direct evidence of a role for the importance of the IL-1 system in implantation comes from studies of mice receiving recombinant IL-1ra prior to implantation. IL-1ra administration blocked blastocyst implantation in these animals (57). However, matings between mice deficient for IL-1RtI showed no apparent implantation failure and only a mild reduction in total litter sizes (58).

Leukemia inhibitory factor (LIF) is a cytokine of the IL-6 family, which includes IL-6 and IL-11 among others (59). It signals through a heterodimeric receptor complex containing a LIF-specific LIF receptor (LIF-R) chain and a promiscuous gp130 chain which is a common subunit for all receptor complexes of the IL-6 family (60-62). A wide range of hormones, cytokines and growth factors have been shown to induce the expression of LIF, including TGF- α , TNF- β , IL-1, estrogen, epidermal growth factor (EGF), and platelet-derived growth factor (63-68). LIF expression has been reported in a variety of organs, including uterus, embryonic blastocyst, thymus, lung, cardiac muscle, kidney, liver, and skin (69-76). In these organs, LIF exerts pleiotropic effects, generally regulation of cell differentiation and proliferation (77).

Among the major cells producing LIF in the endometrium are T cells, uterine NK cells, as well as endometrial epithelium itself (78-82). Expression of LIF during murine pregnancy appears to increase in the endometrium at gd 1, drops by gd 3, and peaks again at gd 4 just prior to implantation (68, 83). In humans, endometrial LIF expression increases during the secretory phase of the menstrual cycle, peaking during the implantation window. LIF expression is markedly reduced in the proliferative phase (84, 85).

A critical role for LIF in reproduction has been elucidated from studies involving mice harboring a null mutation for the LIF gene. These mice ovulate and exhibit successful fertilization, but nonetheless are incapable of successful pregnancy due to an absolute failure of blastocyst implantation (86). Although LIF and LIF-R is expressed in both blastocyst and endometrial epithelium during the peri-implantation period, maternal LIF expression appears to be crucial. While LIF^{-/-} mothers are unable to accept the implanting blastocyst, LIF^{-/-} and LIF-R^{-/-} embryos are able to implant in LIF^{+/+} mothers (87, 88). Furthermore, maternal LIF expression appears to be independent of trophoblast involvement as pseudopregnant female mice express endometrial LIF (68). There has also been evidence for a link between LIF and human reproductive success. Several studies have shown a correlation between low levels of LIF in uterine flushings of women during the secretory phase of the menstrual cycle and infertility (89). Moreover, certain deleterious point mutations of the LIF gene have been found in infertile women (90-92).

The mechanisms of LIF's role during implantation are not well understood. LIF has been demonstrated to induce the expression of various factors that are associated with successful implantation, such as Insulin-like growth factor binding protein 3 (IGFBP-3), chorionic gonadotropin, EGF, COX-2, urokinase-type plasminogen activator (uPA), and MMP-9 (93-95). These factors collectively regulate blastocyst adhesion, and trophoblast invasiveness.

Another member of the IL-6 family of cytokines is interleukin-11 (IL-11). Like LIF, IL-11 exhibits pleiotropic effects in many organ systems (96, 97). IL-11 signals through a heterodimeric receptor complex consisting of the common gp130 chain shared by other IL-6 family members and the IL-11-specific receptor IL-11Ra (98). Uterine expression of IL-11 in both mouse and human peaks during the peri-implantation period (99, 100).

Matings of IL-11Ra^{-/-} mice showed that while they experience successful fertilization, embryo attachment, and initial implantation, embryos die soon thereafter (101). Moreover, the success of pregnancy with the transfer of IL-11Ra^{-/-} embryos into IL-11Ra^{+/+} mothers and the failure with the transfer of IL-11Ra^{+/+} embryos into IL-11Ra^{-/-} mothers confirmed a crucial maternal function for IL-11 in early pregnancy. Histological studies of matings between IL-11Ra^{-/-}

mice show a failure of decidualization associated with an overly aggressive invasion of trophoblast into uterine tissue. Indeed, even oil-induced decidualization responses were defective in these mice. These data suggest that IL-11 is crucial for the initiation of uterine decidualization.

Colony Stimulating Factor-1 (CSF-1), also known as macrophage CSF (m-CSF), regulates the differentiation, proliferation, and survival in many cell types (102). This cytokine is highly expressed in the uterine luminal glandular epithelium beginning at gestational day (gd) 3 in murine pregnancy, peaking around gd 14.5 (103, 104). In humans, CSF-1 is expressed throughout the menstrual cycle in humans and is highly expressed in the decidua during the first trimester (105).

A function for CSF-1 in the regulation of pregnancy was first discovered from examinations of osteopetrotic (op/op) mice. These mice possess a frame shift mutation which renders them functionally null for the CSF-1 gene (106). Ovulation rates in op/op mice are dramatically reduced and matings between these mice display reduced implantation and fetal survival. In humans, low serum levels and reduced production of CSF-1 from CD4⁺ T cells are associated with recurrent spontaneous abortion (107). While these results point to a crucial role for CSF-1 during murine and human pregnancy, the mechanism of action are currently unknown.

Interferon-gamma (IFN-gamma) is a cytokine mainly expressed by T cells, NK cells, and NKT cells and can regulate the transcription of about 0.5% of the genome (108). During normal pregnancy, uterine IFN-gamma is expressed mainly by local uterine NK (uNK) cells and also by decidual stromal cells (19, 109). During gestation, exogenous administration of IFN-gamma or infection with pathogens that preferentially induce IFN-gamma is associated with an increase in fetal demise in mice (110). However, mice with an IFN-gamma-null mutation also display increased rates of fetal loss (111). This loss is associated with impaired decidualization and defective remodeling of uterine arteries. Thus, effect of IFN-gamma on pregnancy is complex and seems to depend on the relative balance of production between IFN-gamma and cytokines that exert antagonistic effects, such as interleukin-10 (IL-10).

Interleukin-10 (IL-10) is a cytokine that exerts a wide variety of effects on most immune cell types. In T cells and NK cells, IL-10 has been shown to inhibit proliferation, cytokine production, and cytotoxic activity. IL-10 also suppresses macrophage maturation and antigen presentation (112).

Serum levels and utero-placental levels of IL-10 increase significantly during pregnancy (22, 26, 109, 113-115). At the fetal-maternal interface, it is expressed by placental trophoblast, decidual stromal cells, uNK cells, T cells, and macrophages (116-120). Local expression of IL-10 begins soon after implantation and persists through the second trimester, particularly in humans.

IL-10 is thought to contribute to the success of pregnancy through action on many different tissues and cell types. Consistent with its well-studied immunoregulatory effects during immune responses to pathogens, tumors, and in transplantation, IL-10 appears to influence immunity at the fetal-maternal interface. In the placenta, IL-10 induces the downregulation of classical class I major histocompatibility complex (MHC) expression as well as the upregulation of the non-classical class I MHC molecule human leukocyte antigen (HLA-G) (121-123). This would be expected to have an immunoregulatory effect on the immunogenic potential of the placenta as classical class I MHC serves as a positive ligand for cytotoxic T lymphocytes. Moreover, HLA-G expression has been shown to reduce target cell susceptibility to NK cell-mediated cytotoxicity (124-126).

In addition to potential immunoregulatory roles, IL-10 affects placental development and function. Proper placental function is crucially dependent on the activities of matrix metalloproteinases (MMPs), which serve to degrade the extracellular matrix and facilitate trophoblast invasion of the uterus (127). IL-10 both downregulates the expression of MMPs and induces the expression of the MMP inhibitor, tissue inhibitor of metalloproteinase (TIMP) (128-130). IL-10 also appears to influence the survival of trophoblast cells through the protection from apoptosis (Sharma S, Unpublished data).

Corroboration for a critical role for IL-10 in pregnancy can be found in studies of IL-10 expression patterns in various diseases of human pregnancy. Both circulating and local levels of IL-10 appear to be diminished in human pregnancy complications such as recurrent spontaneous abortion (RSA), preterm birth, and pre-eclampsia (131-138). Furthermore, fetal demise in an abortion-prone mouse mating model has been associated with low IL-10 production (139). However, mating of IL-10^{-/-} showed no defect in either syngeneic or allogeneic pregnancy as compared to wild type controls (140). Although pregnancy is successful, IL-10^{-/-} mice exhibit larger and more deeply penetrating placentas (141). This finding is consistent with an abrogation of the regulatory activity that IL-10 exerts on MMPs, which would favor deeper trophoblast invasion into the decidua. While pregnancy appears largely unaffected in IL-10^{-/-} mice, initially-studied mating took place under pathogen-free conditions. However, when pregnant IL-10^{-/-} mice are challenged with very low doses of inflammatory agents, they exhibit multitude of pregnancy-associated complications such as fetal loss, preterm birth, and IUGR. These abnormalities in IL-10^{-/-} mice appear to be largely due to the inability to suppress anti-fetal uNK cell activity (Murphy *et al.*, J Immunol (in press), 2005).

4.2. Cyclooxygenase-2

The involvement of prostaglandins in a wide variety of processes crucial for reproduction has been well documented (142-145). These range from implantation, decidualization, and regulation of cell growth and differentiation. Two enzymes are crucial for prostaglandin

synthesis, the constitutively expressed cyclooxygenase-1 (Cox-1) and the inducible cyclooxygenase-2 (Cox-2). These enzymes carry out the rate-limiting reaction in prostaglandin synthesis, the conversion of arachidonic acid into the intermediate endoperoxidases (PGH₂), which are subsequently converted into prostaglandins by specific prostaglandin synthases (146, 147). Cox-2 expression, in particular, seems to be important for successful reproduction. It is expressed in the uterus of both human and mouse, and is associated with blastocyst attachment (148, 149).

Certain strains of Cox-2^{-/-} mice display multiple reproductive difficulties including defects in ovulation, fertilization, implantation, and decidualization (150). However, Cox-1 expression can partially compensate for the lack of Cox-2 expression. Elevated Cox-2 expression is associated with LPS-induced preterm birth and fetal resorption in mouse models (151, 152). In humans, differential Cox-2 expression patterns have been associated with several pregnancy-associated diseases. While elevated Cox-2 expression has been associated with endometriosis and preterm birth, decreased Cox-2 expression is implicated in some cases of pre-eclampsia (153-158).

4.3. Insulin like growth factor system

The insulin like growth factors (IGF) system appears to play a central role in most reproductive processes studied in both laboratory animals and humans. IGFs are mitogens that regulate cellular growth and metabolism throughout the body, but appear to play an especially crucial role in reproduction (159-161). The members of the IGF system include two soluble peptides, IGF-I and IGF-II, six IGF binding proteins (IGFBP-1 through IGFBP-6), as well as two transmembrane receptors (IGFR type I and type II). Both IGF I and II are highly homologous peptides, structurally related to insulin. Both IGFs can signal through both IGF receptors, but the major signaling receptor appears to be IGFR type I. IGFR type II preferentially binds IGF-II but appears to only be responsible for the internalization and turnover of IGF-II (162, 163). The six IGFBPs bind IGFs with a much higher affinity than either of the IGF receptors, with their affinity for IGFs increased with phosphorylation (164).

The expression of the members of the IGF system is highly regulated during pregnancy. In humans, mRNA for both IGF-I and IGF-II are expressed in the mid to late proliferative and early secretory phase of the menstrual cycle (165). In mice, there is also a cyclical pattern of IGF expression during the estrous cycle (167). The type I IGF receptor is constitutively expressed in the endometrium of both mice and humans, although human endometrium also expresses the type II receptor (166-168). All six IGFBPs are expressed in humans with IGFBP-1 being predominant in the late secretory phase endometrium (33, 169). Expression of IGFBP-3, -4, and -5 is found within the mouse decidua with IGFBP-4 expression being highly localized to implantation site 24 hours after blastocyst implantation (170, 171). During gestation, mRNAs from all members of the IGF system are expressed in the human placenta (161, 171).

The temporal and spatial expression of members of the IGF system suggests a role for their paracrine regulation of fetal and maternal tissues during gestation, especially the processes of implantation and decidualization. Further insights into the functions of the IGF system during pregnancy have been gleaned from knockout mouse models. IGF-I^{-/-} animals display reduced growth during embryonic and postnatal stages (172). Mating of male IGF-II^{-/-} mice to IGF-II^{+/+} females resulted in embryonic growth restriction but normal growth rates, although the absolute size of heterozygous progeny was reduced as compared to wild type (173). Mice functionally null for the type I IGF receptor exhibit severe embryonic growth restriction, a result to be expected considering the loss of both IGF-I and IGF-II signaling (172). Interestingly, while neither IGF-I^{-/-} nor type I IGF-R^{-/-} animals display abnormalities in placental growth and development, IGF-II^{+/+} embryos exhibit decreased placental growth, suggesting an important role of IGF-II in placental development (174).

4.4. Matrix Metalloproteinase System

Matrix metalloproteinases (MMPs) are a family of extracellular matrix degrading enzymes which include MMP-1 through MMP-28 (175). Their actions are regulated in the tissues by a group of MMP inhibitors referred to as tissue inhibitors of metalloproteinases (TIMPs). To date, four TIMPs have been discovered, TIMPs1-4, which appear to each have selective activities on specific MMPs (175).

The expression of many MMPs is observed during pregnancy in rodents, although most studies agree that MMP-2 and MMP-9 are likely to be most crucial for reproduction (176). It appears that the most important factors regulating MMP expression and activity during pregnancy are cytokines. Among the most studied is the IL-1 family. IL-1 α and IL-1 β expression in blastocysts and invasive trophoblasts seems to be important in the upregulation of MMP expression (177). Moreover, IL-1 β administration upregulates MMP expression in both maternal and placental tissues. In addition to enhancing the expression and activity of MMPs, various cytokines can downregulate MMP activity. Most notably, IL-10 is known to both inhibit the expression of MMP-2 and MMP-9 and upregulate the expression of TIMP-1 (178-180).

Several mouse strains have been created with targeted gene knockouts of members of the MMP system. With initial inspection, there appeared to be no overt reproductive phenotypes. This may, in part be due to an inherent redundancy and compensatory nature of the MMP system. Deletion of a single MMP or TIMP gene seems to result in the compensation by other MMPs or TIMPs. For example, while MMP-7 and MMP-3 knockout mice appear to reproduce normally, MMP-3 and MMP-7 expression appears to be upregulated in these mice respectively (181, 182).

Moreover, closer investigation revealed subtle reproductive defects in mice with MMP-family gene knockouts. MMP-9 knockout mice appear to have no obvious reproductive phenotype, however, they present smaller litter sizes and reduced pregnancy rates after copulation (183, 184). In addition, TIMP-1 knockout mice are able to reproduce, but display reduced pregnancy rates with fewer pups per litter (185, 186).

4.5. Transcription Factors Involved in Placental Development

The expression of a vast array of transcription factors in placental cells has been shown to be crucial in the differentiation of the various trophoblast-derived cell types. Of these, a select few knockout mouse models are available. Among the best studied are Hand1 and Gcm1. Hand1 is a basic helix-loop-helix transcription factor that serves to induce trophoblast growth arrest and differentiation to giant cells, an invasion trophoblast-derived cell which functions in the establishment of an efficient fetal-maternal vascular exchange (187, 188). Gcm1 is an unrelated transcription factor expressed in the placental labyrinth (189). Mice with a Gcm1-null mutation display defects in chorioallantoic fusion and syncytiotrophoblast differentiation (190).

4.6. Indoleamine-2,3-dioxygenase

Indoleamine-2,3-dioxygenase (IDO) is a tryptophan catabolizing enzyme expressed in a variety of cell types at the fetal-maternal interface (191). Pharmacological inhibition of IDO in pregnant mice from wild type allogeneic matings resulted in increased fetal demise, which was not observed in wild type syngeneic matings (192). Inhibition of IDO in pregnant RAG-2^{-/-} or SCID mice from allogeneic matings had no effect on pregnancy outcome, suggesting that the major regulatory target cell for IDO activity is T cells (193). However, matings between allogeneic IDO knockout mice display no reproductive defect (194). This suggests that in the absence of IDO, the T cell activity could be controlled by compensatory and redundant mechanisms or that pharmacological targeting of IDO in pregnant mice influenced some other pathways.

5. CONCLUSIONS

The use of gene knockout mice has greatly increased understanding of the roles of specific genes involved in the processes of implantation and fetal development (Table 1). While the expression of some genes is of such importance for these processes that their absence prevents reproduction, others appear to exist in a redundant network. This redundancy obscures the interpretation of the physiological significance of the absence of a specific gene. This phenomenon of redundancy, while greatly prominent in the processes involved in reproduction, is a common pitfall of research using gene knockout mice. It is likely that the investigation of the role of gene deficiency in reproduction will be greatly aided by understanding the contribution of secondary, often temporally encountered insults.

Table 1. Gene Knockouts Affecting Reproduction

Gene	Pattern of Expression	Knockout Reproductive Phenotype	References
IL-1RtI	Preimplantation blastocyst and maternal endometrium	Slight reduction in litter sizes	59
LIF	Endometrium, uNK cells, uterine T cells	Complete failure of blastocyst implantation	87-89
IL-11R α	Uterine endometrium, uNK cells, uterine T cells	Failure of decidualization, early embryonic death	102
CSF-1	Uterine endometrium	Reduced ovulation and implantation rates	107
IFN- γ	Uterine endometrium, uNK cells, uterine T cells	Primiparous reproductive defects, moderate failure of decidualization	112
IL-10	Uterine endometrium, NK cells, uterine T cells, placenta	Exaggerated inflammatory response to mild inflammatory insults leading to uNK cell-mediated fetal loss, prematurity, and IUGR	141, 142
COX-2	Uterine endometrium, placenta	Defects in ovulation, fertilization, implantation, and decidualization	151
IGF-I	Uterine endometrium	Reduced growth during embryonic and postnatal stages	173
IGF-II	Uterine endometrium	Reduced embryonic growth and placental defects	174
type I IGF-R	Uterine endometrium	Severe embryonic growth restriction	175
MMP-3, -7, -9	Uterine endometrium, uterine immune cells, placenta	Smaller litter sizes and reduced pregnancy rates, Compensation by remaining MMP family members	182-185
TIMP-1	Uterine endometrium	Reduced pregnancy rates with fewer pups per litter	186, 187
Hand1	Placental trophoblast	Failure in trophoblast differentiation to Giant cells	188, 189
Gcm1	Placental labyrinth	Defects in chorioallantoic fusion and syncytiotrophoblast differentiation	191
IDO	Uterine endometrium, uterine macrophages, placenta	None reported. Pharmacological inhibition results in failure of allogeneic pregnancies	195

6. ACKNOWLEDGEMENTS

This work was supported by National Institutes of Health grants HD41701 and P20RR018728.

7. REFERENCES

- Vigano P, Mangioni S, Pompei F, and Chiodo I. Maternal-conceptus cross talk--a review. *Placenta*.24, Suppl B:S56-61 (2003)
- Dominguez F, Pellicer A, and Simon C. The chemokine connection: hormonal and embryonic regulation at the human maternal-embryonic interface--a review. *Placenta* 24 Suppl B:S48-55 (2003)
- Saito S. Cytokine cross-talk between mother and the embryo/placenta. *J Reprod Immunol* 52, 15-33 (2001)
- Wegmann TG. The cytokine basis for cross-talk between the maternal immune and reproductive systems. *Curr Opin Immunol* 2, 765-69 (1989)
- Paria BC, Reese J, Das SK, Dey SK. Deciphering the cross-talk of implantation: advances and challenges. *Science* 21, 2185-2188 (2002)
- Simon C, Mercader A, Gimeno MJ, Pellicer A. The interleukin-1 system and human implantation. *Am J Reprod Immunol* 37, 64-72 (1997)
- Aghajanova L. Leukemia inhibitory factor and human embryo implantation. *Ann N Y Acad Sci* 1034, 176-183 (2004)
- Barnea ER. Insight into early pregnancy events: the emerging role of the embryo. *Am J Reprod Immunol* 51, 1-4 (2004)
- Rosario GX, Modi DN, Sachdeva G, Manjramkar DD, Puri CP. Morphological events in the primate endometrium in the presence of a preimplantation embryo, detected by

the serum preimplantation factor bioassay. *Hum Reprod* 20, 61-71 (2005)

- Evain-Brion D. Hormonal regulation of fetal growth. *Horm Res* 42, 207-214 (1994)
- Anthony RV, Pratt SL, Liang R, Holland MD. Placental-fetal hormonal interactions: impact on fetal growth. *J Anim Sci* 73, 1861-1871 (1995)
- Gluckman PD, Harding JE. The physiology and pathophysiology of intrauterine growth retardation. *Horm Res Suppl* 1, 11-16 (1997)
- Baumann MU, Deborde S, Illsley NP. Placental glucose transfer and fetal growth. *Endocrine* 19, 13-22 (2002)
- Georgiades P, Ferguson-Smith AC, Burton GJ. Comparative developmental anatomy of the murine and human definitive placentae. *Placenta* 23, 3-19 (2002)
- Godfrey KM. Maternal regulation of fetal development and health in adult life. *Eur J Obstet Gynecol Reprod Biol* 78, 141-150 (1998)
- Alexander CM, Hansell EJ, Behrendtsen O, Flannery ML, Kishnani NS, Hawkes SP, Werb Z. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. *Development* 122, 1723-1736 (1996)
- Sharkey ME, Adler RR, Nieder GL, Brenner CA. Matrix metalloproteinase expression during mouse peri-implantation development. *Am J Reprod Immunol* 36, 72-80 (1996)
- Das SK, Yano S, Wang J, Edwards DR, Nagase H, Dey SK. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. *Dev Genet* 21, 44-54 (1997)

19. Ashkar AA, Croy BA. Functions of uterine natural killer cells are mediated by interferon gamma production during murine pregnancy. *Semin Immunol* 13, 235-241 (2001)
20. Ain R, Canham LN, Soares MJ. Gestation stage-dependent intrauterine trophoblast cell invasion in the rat and mouse: novel endocrine phenotype and regulation. *Dev Biol* 260, 176-190 (2003)
21. Cadet P, Rady PL, Tying SK, Yandell RB, Hughes TK. Interleukin-10 messenger ribonucleic acid in human placenta: implications of a role for interleukin-10 in fetal allograft protection. *Am J Obstet Gynecol* 173, 25-29 (1995)
22. Roth I, Corry DB, Locksley RM, Abrams JS, Litton MJ, Fisher SJ. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. *J Exp Med* 184, 539-548 (1996)
23. Bennett WA, Lagoo-Deenadayalan S, Whitworth NS, Brackin MN, Hale E, Cowan BD. Expression and production of interleukin-10 by human trophoblast: relationship to pregnancy immunotolerance. *Early Pregnancy* 3, 190-198 (1997)
24. Trautman MS, Collmer D, Edwin SS, White W, Mitchell MD, Dudley DJ. Expression of interleukin-10 in human gestational tissues. *J Soc Gynecol Investig* 4, 247-253 (1997)
25. Dudley DJ, Edwin SS, Dangerfield A, Jackson K, Trautman MS. Regulation of decidual cell and chorion cell production of interleukin-10 by purified bacterial products. *Am J Reprod Immunol* 38, 246-251 (1997)
26. Hanna N, Hanna I, Hleb M, Wagner E, Dougherty J, Balkundi D, Padbury J, Sharma S. Gestational age-dependent expression of IL-10 and its receptor in human placental tissues and isolated cytotrophoblasts. *J Immunol* 164, 5721-5728 (2000)
27. Wu MY, Chen HF, Chen SU, Chao KH, Yang YS, Ho HN. Increase in the production of interleukin-10 early after implantation is related to the success of pregnancy. *Am J Reprod Immunol* 46, 386-92 (2001)
28. Reese J, Das SK, Paria BC, Lim H, Song H, Matsumoto H, Knudtson KL, DuBois RN, Dey SK. Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation. *J Biol Chem* 276, 44137-44145 (2001)
29. Lobo SC, Huang ST, Germeyer A, Dosiou C, Vo KC, Tulac S, Nayak NR, Giudice LC. The immune environment in human endometrium during the window of implantation. *Am J Reprod Immunol* 52, 244-251 (2004)
30. Riesewijk A, Martín J, van Roselinde Os, Horcajadas JA, Polman J, Pellicer A, Mosselman S, Simon C. Gene expression profiling of human endometrial receptivity on days LH+2 versus LH+7 by microarray technology. *Mol Hum Reprod* 9, 253-264, (2003)
31. Julkunen M, Raikar RS, Joshi SG, Bohn H, Seppala M. Placental protein 14 and progesterone-dependent endometrial protein are immunologically indistinguishable. *Hum Reprod* 1, 7-8 (1986)
32. Apparao KB, Murray MJ, Fritz MA, Meyer WR, Chambers AF, Truong PR, Lessey BA. Osteopontin and its receptor alphavbeta(3) integrin are coexpressed in the human endometrium during the menstrual cycle but regulated differentially. *J Clin Endocrinol Metab* 86, 4991-5000 (2001)
33. Zhou J, Dsupin BA, Giudice LC, Bondy CA. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. *J Clin Endocrinol Metab* 79, 1723-1734 (1994)
34. Popovici RM, Kao LC, Giudice LC. Discovery of new inducible genes in *in vitro* decidualized human endometrial stromal cells using microarray technology. *Endocrinology* 141, 3510-3513 (2000)
35. Gruidl M, Buyuksal A, Babaknia A, Fazleabas AT, Sivarajah S, Satyawaroop PG, Tabibzadeh S. The progressive rise in the expression of alpha crystallin B chain in human endometrium is initiated during the implantation window: modulation of gene expression by steroid hormones. *Mol Hum Reprod* 3, 333-342 (1997)
36. Chen HW, Chen JJ, Tzeng CR, Li HN, Chang SJ, Cheng YF, Chang CW, Wang RS, Yang PC, Lee YT. Global analysis of differentially expressed genes in early gestational decidua and chorionic villi using a 9600 human cDNA microarray *Mol Hum Reprod* 8, 475-484 (2002)
37. Tanaka TS, Ko MS. A global view of gene expression in the preimplantation mouse embryo: morula versus blastocyst. *Eur J Obstet Gynecol Reprod Biol* 115, S85-91 (2004)
38. Hamatani T, Daikoku T, Wang H, Matsumoto H, Carter MG, Ko MS, Dey SK. Global gene expression analysis identifies molecular pathways distinguishing blastocyst dormancy and activation. *Proc Natl Acad Sci U S A* 101, 10326-10331 (2004)
39. Dobson AT, Raja R, Abeyta MJ, Taylor T, Shen S, Haqq C, Pera RA. The unique transcriptome through day 3 of human preimplantation development. *Hum Mol Genet* 13, 1461-1470 (2004)
40. Tanaka TS, Jaradat SA, Lim MK, Kargul GJ, Wang X, Grahovac MJ, Pantano S, Sano Y, Piao Y, Nagaraja R, Doi H, Wood WH 3rd, Becker KG, Ko MS. Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. *Proc Natl Acad Sci U S A* 97, 9127-9132 (2000)
41. Dinarello CA. The interleukin-1 family: 10 years of discovery. *FASEB J* 8, 1314-1325 (1994)

42. Sims JE, Giri JG, Dower SK. The two interleukin-1 receptors play different roles in IL-1 actions. *Clin Immunol Immunopathol* 72, 9-14 (1994)
43. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdahl PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. *Nature* 25, 336-340 (1990)
44. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. *Nature* 343, 341-346 (1990)
45. McIntyre KW, Stepan GJ, Kolinsky KD, Benjamin WR, Plocinski JM, Kaffka KL, Campen CA, Chizzonite RA, Kilian PL. Inhibition of interleukin 1 (IL-1) binding and bioactivity *in vitro* and modulation of acute inflammation *in vivo* by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. *J Exp Med* 173, 931-939 (1991)
46. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. *J Biol Chem* 266, 10331-10336 (1991)
47. Simon C, Frances A, Piquette GN, Heindrickson M, Milki A, Polan ML. Interleukin-1 system in the materno-trophoblast unit in human implantation: Immunohistochemical evidence for autocrine/paracrine function. *J Clin Endocrinol Metab* 78, 847-854 (1994)
48. Simon C, Frances A, Lee BY, Mercader A, Huynh T, Remohi J, Polan ML, Pellicer A. Immunohistochemical localization, identification and regulation of the interleukin-1 receptor antagonist in the human endometrium. *Hum Reprod* 10, 2472-2477 (1995)
49. Liang L, Kover K, Dey SK, Andrews GK. Regulation of interleukin-6 and interleukin-1 beta gene expression in the mouse deciduum. *J Reprod Immunol* 30, 29-52 (1996)
50. Takacs P, Kauma S. The expression of interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor type I mRNA during preimplantation mouse development. *J Reprod Immunol* 32, 27-35 (1996)
51. Simon C, Mercader A, Gimeno MJ, Pellicer A. The interleukin-1 system and human implantation. *Am J Reprod Immunol* 37, 64-72 (1997)
52. Krussel JS, Simon C, Rubio MC, Pape AR, Wen Y, Huang HY, Bielfeld P, Polan ML. Expression of interleukin-1 system mRNA in single blastomeres from human preimplantation embryos. *Hum Reprod* 13, 2206-2211 (1998)
53. Tanaka T, Sakamoto T, Mizuno K, Umesaki N, Ogita S. Human endometrial stromal interleukin-1 beta: autocrine secretion and inhibition by interleukin-1 receptor antagonist. *Horm Res* 53, 300-304 (2000)
54. Bigonnesse F, Labelle Y, Akoum A. Triphasic expression of interleukin-1 receptor type I in human endometrium throughout the menstrual cycle of fertile women and women with unexplained infertility. *Fertil Steril* 75, 79-87 (2001)
55. Simon C, Frances A, Piquette GN, el Danasouri I, Zurawski G, Dang W, Polan ML. Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist. *Endocrinology* 134, 521-528 (1994)
56. Hirsch E, Blanchard R, Mehta SP. Differential fetal and maternal contributions to the cytokine milieu in a murine model of infection-induced preterm birth. *Am J Obstet Gynecol* 180, 429-434 (1999)
57. Simon C, Frances A, Piquette GN, el DI, Zurawski G, Dang W, and Polan ML. Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist. *Endocrinology* 134, 521-528 (1994)
58. Abbondanzo SJ, Cullinan EB, McIntyre K, Labow MA, Stewart CL. Reproduction in mice lacking a functional type 1 IL-1 receptor. *Endocrinology* 137, 3598-5601 (1996)
59. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. *Annu Rev Immunol* 15, 797-819 (1997)
60. Taupin JL, Pitard V, Dechanet J, Miossec V, Gualde N, Moreau JF. Leukemia inhibitory factor: part of a large ingathering family. *Int Rev Immunol* 16, 397-426 (1998)
61. Gearing DP, Thut CJ, VandeBos T, Gimpel SD, Delaney PB, King J, Price V, Cosman D, Beckmann MP. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. *EMBO J* 10, 2839-2848 (1991)
62. Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. *J Exp Med* 179, 1337-1342 (1994)
63. Arici A, Engin O, Attar E, Olive DL. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. *J Clin Endocrinol Metab* 80, 1908-1915 (1995)
64. Wetzler M, Talpaz M, Lowe DG, Baiocchi G, Gutterman JU, Kurzrock R. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. *Exp Hematol* 19, 347-351 (1991)
65. Schluns KS, Cook JE, Le PT. TGF-beta differentially modulates epidermal growth factor-mediated increases in

leukemia-inhibitory factor, IL-6, IL-1 alpha, and IL-1 beta in human thymic epithelial cells. *J Immunol* 158, 2704-2712 (1997)

66. Matsuoka I, Nakane A, Kurihara K. Induction of LIF-mRNA by TGF-beta 1 in Schwann cells. *Brain Res* 776, 170-180 (1997)

67. Yang ZM, Chen DB, Le SP, Harper MJ. Differential hormonal regulation of leukemia inhibitory factor (LIF) in rabbit and mouse uterus. *Mol Reprod Dev* 43, 470-476 (1996)

68. Bhatt H, Brunet LJ, Stewart CL. Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation. *Proc Natl Acad Sci U S A* 88, 11408-11412 (1991)

69. Sempowski GD, Hale LP, Sundy JS, Massey JM, Koup RA, Douek DC, Patel DD, Haynes BF. Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. *J Immunol* 164, 2180-2187 (2000)

70. McKenzie RC, Szepletowski JC. Leukaemia inhibitory factor (LIF) expression in skin from myotrophic lateral sclerosis patients compared with skin from normal individuals: what is the function of LIF in the skin? *J Invest Dermatol* 116, 476-478 (2001)

71. Ni H, Ding NZ, Harper MJ, Yang ZM. Expression of leukemia inhibitory factor receptor and gp130 in mouse uterus during early pregnancy. *Mol Reprod Dev* 63, 143-150 (2002)

72. Robertson M, Chambers I, Rathjen P, Nichols J, Smith A. Expression of alternative forms of differentiation inhibiting activity (DIA/LIF) during murine embryogenesis and in neonatal and adult tissues. *Dev Genet* 14, 165-173 (1993)

73. Blanche G, Moreau JF, Chabannes D, Chatenoud L, Souillou JP. HILDA/LIF, G-CSF, IL-1 beta, IL-6, and TNF alpha production during acute rejection of human kidney allografts. *Transplantation* 56,597-602 (1993)

74. Tomida M, Yamamoto-Yamaguchi Y, Hozumi M. Pregnancy associated increase in mRNA for soluble D factor/LIF receptor in mouse liver. *FEBS Lett* 334, 193-197 (1993)

75. Knight DA, Lydell CP, Zhou D, Weir TD, Schellenberg R, Bai TR. Leukemia inhibitory factor (LIF) and LIF receptor in human lung. Distribution and regulation of LIF release. *Am J Respir Cell Mol Biol*. 20, 834-41 (1999)

76. Jougasaki M, Leskinen H, Larsen AM, Cataliotti A, Chen HH, Burnett JC Jr. Leukemia inhibitory factor is augmented in the heart in experimental heart failure. *Eur J Heart Fail* 5, 137-145 (2003)

77. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. *Stem Cells* 21, 5-14 (2003)

78. Shen MM, Leder P. Leukemia inhibitory factor is expressed by the preimplantation uterus and selectively blocks primitive ectoderm formation *in vitro*. *Proc Natl Acad Sci U S A* 89, 8240-8244 (1992)

79. Kojima K, Kanzaki H, Iwai M, Hatayama H, Fujimoto M, Inoue T, Horie K, Nakayama H, Fujita J, Mori T. Expression of leukemia inhibitory factor in human endometrium and placenta. *Biol Reprod* 50, 882-887 (1994)

80. Yang ZM, Le SP, Chen DB, Cota J, Siero V, Yasukawa K, Harper MJ. Leukemia inhibitory factor, LIF receptor, and gp130 in the mouse uterus during early pregnancy. *Mol Reprod Dev* 42, 407-414 (1995)

81. Saito S, Nishikawa K, Morii T, Enomoto M, Narita N, Motoyoshi K, Ichijo M. Cytokine production by CD16⁺CD56^{bright} natural killer cells in the human early pregnancy deciduas. *Int Immunol* 5, 559-563 (1993)

82. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. *Nat Med* 4, 1020-1024 (1998)

83. Song H, Lim H, Das SK, Paria BC, and Dey SK. Dysregulation of EGF family of growth factors and COX-2 in the uterus of preattachment and attachment reactions of the blastocyst with the luminal epithelium correlates with implantation failure in LIF-deficient mice. *Molecular Endocrinology*. 14, 1147-1161 (2000)

84. Arici A, Engin O, Attar E, Olive DL. Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. *J. Clin. Endocrinol Metab*. 80, 1908-1915 (1995)

85. Nachtigall MJ, Kliman HJ, Feinberg RF, Olive DL, Engin O, Arici A. The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: a potential role in human reproduction. *J. Clin. Endocrinol. Metab*. 81, 801-806 (1996)

86. Stewart CL, Kasper P, Brunet LJ, Bhatt H, Gadi I, Kontgen F, and Abbondanzo SJ. Blastocyst implantation depends on maternal expression of leukemia inhibitory factor. *Nature* 359, 76-79 (1992.)

87. Ware CB, Horowitz MC, Renshaw BR, Hunt JS, Liggitt D, Koblar SA, Gliniak BC, McKenna HJ, Papayannopoulou T, Thoma B, Cheng L, Donovan PJ, Peschon JJ, Bartlett PF, Willis CR, Wright BD, Carpenter MK, Davison BL, Gearing DP. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural, and metabolic defects and results in perinatal death. *Development* 121, 1283-1299 (1995)

88. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T. Targeted disruption of gp130, a common signal transducer for the interleukin-6 family of cytokines, leads to myocardial and hematological disorders. *Proc Natl Acad Sci USA* 93, 407-411 (1996)
89. Laird SM, Tuckerman EM, Dalton CF, Dunphy BC, Li TC, Zhang X. The production of leukaemia inhibitory factor by human endometrium: presence in uterine flushings and production by cells in culture. *Hum Reprod* 12, 569-574 (1997)
90. Giess R, Tanasecu I, Steck T, Sendtner M. Leukemia inhibitory factor gene mutations in infertile women. *Mol Hum Reprod* 5, 581-586 (1999)
91. Steck T, Giess R, Suetterlin MW, Bolland M, Wiest S, Poehls UG, Dietl J. Leukemia inhibitory factor (LIF) gene mutations in women with unexplained infertility and recurrent failure of implantation after IVF and embryo transfer. *Eur J Obstet Gynecol Reprod Biol* 112, 69-73 (2004)
92. Robinson RC, Grey LM, Staunton D, Vankelecom H, Vernallis AB, Moreau JF, Stuart DI, Heath JK, Jones EY. The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding. *Cell* 77, 1101-1116 (1994)
93. Sherwin JR, Freeman TC, Stephens RJ, Kimber S, Smith AG, Chambers I, Smith SK, Sharkey AM. Identification of genes regulated by leukemia-inhibitory factor in the mouse uterus at the time of implantation. *Mol Endocrinol* 18, 2185-2195 (2004)
94. Sawai K, Matsuzaki N, Kameda T, Hashimoto K, Okada T, Shimoya K, Nobunaga T, Taga T, Kishimoto T, Saji F. Leukemia inhibitory factor produced at the fetomaternal interface stimulates chorionic gonadotropin production: its possible implication during pregnancy, including implantation period. *J Clin Endocrinol Metab* 80, 1449-1456 (1995)
95. Harvey MB, Leco KJ, Arcellana-Panlilio MY, Zhang X, Edwards DR, Schultz GA. Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor. *Development* 121, 1005-1014 (1995)
96. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. *Gastroenterology* 117, 58-64 (1999)
97. Keith JC Jr, Albert L, Sonis ST, Pfeiffer CJ, Schaub RG. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. *Stem Cells* 12, 79-87 (1994)
98. Neben S, Turner K. The biology of interleukin 11. *Stem Cells* 11, 156-162 (1993)
99. Cork BA, Li TC, Warren MA, Laird SM. Interleukin-11 (IL-11) in human endometrium: expression throughout the menstrual cycle and the effects of cytokines on endometrial IL-11 production *in vitro*. *J Reprod Immunol* 50, 3-17 (2001)
100. Zourbas S, Dubanchet S, Martal J, Chaouat G. Localization of pro-inflammatory (IL-12, IL-15) and anti-inflammatory (IL-11, IL-13) cytokines at the foetomaternal interface during murine pregnancy. *Clin Exp Immunol* 126, 519-528 (2001)
101. Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. *Nat Med* 4, 303-308 (1998)
102. Stanley ER, Guilbert LJ, Tushinski RJ, Bartelmez SH. CSF-1--a mononuclear phagocyte lineage-specific hemopoietic growth factor. *J Cell Biochem* 21, 151-159 (1983)
103. Pollard JW, Bartocci A, Arceci R, Orlofsky A, Ladner MB, Stanley ER. Apparent role of the macrophage growth factor, CSF-1, in placental development. *Nature* 330, 484-486 (1987)
104. Arceci RJ, Shanahan F, Stanley ER, Pollard JW. Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development. *Proc Natl Acad Sci U S A* 86, 8818-8822 (1989)
105. Kauma SW, Aukerman SL, Eierman D, Turner T. Colony-stimulating factor-1 and c-fms expression in human endometrial tissues and placenta during the menstrual cycle and early pregnancy. *J Clin Endocrinol Metab* 73, 746-751 (1991)
106. Pollard JW, Hunt JS, Wiktor-Jedrzejczak W, Stanley ER. A pregnancy defect in the osteopetrotic (op/op) mouse demonstrates the requirement for CSF-1 in female fertility. *Dev Biol* 148, 273-283 (1991)
107. Katano K, Matsumoto Y, Ogasawara M, Aoyama T, Ozaki Y, Kajiura S, Aoki K. Low serum M-CSF levels are associated with unexplained recurrent abortion. *Am J Reprod Immunol* 38, 1-5 (1997)
108. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. *Annu. Rev. Immunol.* 15, 749-795 (1997)

109. Plevyak M, Hanna N, Mayer S, Murphy S, Pinar H, Fast L, Ekerfelt C, Ernerudh J, Berg G, Matthiesen L, Sharma S. Deficiency of decidual IL-10 in first trimester missed abortion: a lack of correlation with the decidual immune cell profile. *Am J Reprod Immunol* 47, 242-250 (2002)
110. Vassiliadis, S., D. Tsoukatos, and I. Athanassakis. Interferon-induced class II expression at the spongiotrophoblastic zone of the murine placenta is linked to fetal rejection and developmental abnormalities. *Acta Physiol. Scand* 151, 485-495 (1994)
111. Ashkar AA, Croy BA. Interferon-gamma contributes to the normalcy of murine pregnancy. *Biol Reprod.* 61, 493-502 (1999)
112. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol* 683-765 (2001)
113. Wu MY, Chen HF, Chen SU, Chao KH, Yang YS, Ho HN. Increase in the production of interleukin-10 early after implantation is related to the success of pregnancy. *Am J Reprod Immunol* 46, 386-392 (2001)
114. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. *J Immunol* 151, 4562-4573. (1993)
115. Trautman MS, Collmer D, Edwin SS, White W, Mitchell MD, Dudley DJ. Expression of interleukin-10 in human gestational tissues. *J Soc Gynecol Investig* 4, 247-253 (1997)
116. Rieger L, Hofmeister V, Probe C, Dietl J, Weiss EH, Steck T, Kammerer U. Th1- and Th2-like cytokine production by first trimester decidual large granular lymphocytes is influenced by HLA-G and HLA-E. *Mol Hum Reprod* 8, 255-61 (2002)
117. Piccinni MP. T-cell cytokines in pregnancy. *Am J Reprod Immunol* 2002 47, 289-294.
118. Nagaeva O, Jonsson L, Mincheva-Nilsson L. Dominant IL-10 and TGF-beta mRNA expression in gamma delta T cells of human early pregnancy decidua suggests immunoregulatory potential. *Am J Reprod Immunol* 48, 9-17 (2002)
119. Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. *Am J Reprod Immunol* 48, 77-86 (2002)
120. Lidstrom C, Matthiesen L, Berg G, Sharma S, Ernerudh J, Ekerfelt C. Cytokine secretion patterns of NK cells and macrophages in early human pregnancy decidua and blood: implications for suppressor macrophages in decidua. *Am J Reprod Immunol* 50, 444-452 (2003)
121. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. *Int Immunol* 11, 803-811 (1999)
122. Rizzo R, Hviid TV, Stignani M, Balboni A, Grappa MT, Melchiorri L, Baricordi OR. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. *Immunogenetics.* 57, 172-181 (2005)
123. Kundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. *Cell Immunol* 180, 55-61 (1997)
124. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? *Proc Natl Acad Sci U S A* 94, 5249-5254 (1997)
125. Adrian Cabestre F, Moreau P, Riteau B, Ibrahim EC, Le Danff C, Dausset J, Rouas-Freiss N, Carosella ED, Paul P. HLA-G expression in human melanoma cells: protection from NK cytotoxicity. *J Reprod Immunol* 43, 183-193 (1999)
126. Park GM, Lee S, Park B, Kim E, Shin J, Cho K, Ahn K. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. *Biochem Biophys Res Commun* 313, 606-611 (2004)
127. Staun-Ram E, Goldman S, Gabarin D, Shalev E. Expression and importance of matrix metalloproteinase 2 and 9 (MMP-2 and -9) in human trophoblast invasion. *Reprod Biol Endocrino.* 2, 59 (2004)
128. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. *J Clin Invest* 96, 2304-2310 (1995)
129. Roth I, Fisher SJ. IL-10 is an autocrine inhibitor of human placental cytotrophoblast MMP-9 production and invasion. *Dev Biol* 205, 194-204 (1999)
130. Yamamoto-Tabata T, McDonagh S, Chang HT, Fisher S, Pereira L. Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness *in vitro*. *J Virol* 78, 2831-2840 (2004)
131. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. *JAMA* 273, 1933-1936 (1995)
132. Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E. Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. *Cell Immunol* 196, 122-130 (1999)

133. Hennessy A, Pilmore HL, Simmons LA, Painter DM. A deficiency of placental IL-10 in preeclampsia. *J Immunol* 163, 3491-3495 (1999)
134. Darmochwal-Kolarz D, Rolinski J, Leszczynska-Goarzelak B, Oleszczuk J. The expressions of intracellular cytokines in the lymphocytes of preeclamptic patients. *Am J Reprod Immunol* 48, 381-386 (2002)
135. Makhseed M, Raghupathy R, El-Shazly S, Azizieh F, Al-Harmi JA, Al-Azemi MM. Pro-inflammatory maternal cytokine profile in preterm delivery. *Am J Reprod Immunol* 49, 308-318 (2003)
136. Rein DT, Breidenbach M, Honscheid B, Friebe-Hoffmann U, Engel H, Gohring UJ, Uekermann L, Kurbacher CM, Schondorf T. Preeclamptic women are deficient of interleukin-10 as assessed by cytokine release of trophoblast cells *in vitro*. *Cytokine* 23, 119-125 (2003)
137. Peltier MR. Immunology of term and preterm labor. *Reprod Biol Endocrinol* 1, 122 (2003)
138. Hossein H, Mahroo M, Abbas A, Firouzeh A, Nadia H. Cytokine production by peripheral blood mononuclear cells in recurrent miscarriage. *Cytokine* 28, 83-86 (2004)
139. Chaouat G, Assal Meliani A, Martal J, Raghupathy R, Elliot J, Mosmann T, Wegmann TG. IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by *in vivo* injection of IFN- τ . *J Immunol* 154, 4261-4268 (1995)
140. White CA, Johansson M, Roberts CT, Ramsay AJ, Robertson SA. Effect of interleukin-10 null mutation on maternal immune response and reproductive outcome in mice. *Biol Reprod* 70, 123-123 (2004)
141. Roberts CT, White CA, Wiemer NG, Ramsay A, Robertson SA. Altered placental development in interleukin-10 null mutant mice. *Placenta* 24, S94-99 (2003)
142. Majerus PW. Prostaglandins: critical roles in pregnancy and colon cancer. *Curr Biol* 8, R87-89 (1998)
143. Slater DM, Zervou S, Thornton S. Prostaglandins and prostanoid receptors in human pregnancy and parturition. *J Soc Gynecol Investig* 9, 118-24 (2002)
144. Saito S, Tsuda H, Michimata T. Prostaglandin D2 and reproduction. *Am J Reprod Immunol* 47, 295-302 (2002)
145. Adelizzi RA. COX-1 and COX-2 in health and disease. *J Am Osteopath Assoc* 99, S7-12 (1999)
146. McCormack K. Roles of COX-1 and COX-2. *J Rheumatol* 25, 2279-2281 (1998)
147. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. *J Biol Chem* 274, 22903-22906 (1999)
148. Marions L, Danielsson KG. Expression of cyclooxygenase in human endometrium during the implantation period. *Mol Hum Reprod* 5, 961-965 (1999)
149. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK. Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR δ . *Genes Dev* 13, 1561-1574 (1999)
150. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. *Cell* 91, 197-208 (1997)
151. Silver RM, Edwin SS, Trautman MS, Simmons DL, Branch DW, Dudley DJ, Mitchell MD. Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. *J Clin Invest* 95, 725-731 (1995)
152. Gross G, Imamura T, Vogt SK, Wozniak DF, Nelson DM, Sadovsky Y, Muglia LJ. Inhibition of cyclooxygenase-2 prevents inflammation-mediated preterm labor in the mouse. *Am J Physiol Regul Integr Comp Physiol* 278, R1415-1423 (2000)
153. Akarasereenont P, Techatrasak K, Chotewuttakorn S, Thaworn A. The expression of cyclooxygenase-2 in human umbilical vein endothelial cell culture from preeclampsia. *J Med Assoc Thai* ;82, 167-172 (1999)
154. Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. *Hum Reprod* 16, 561-566 (2001)
155. Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N, Yamamoto T, Honda M. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. *Am J Reprod Immunol* 48, 50-56 (2002)
156. Loudon JA, Groom KM, Bennett PR. Prostaglandin inhibitors in preterm labour. *Best Pract Res Clin Obstet Gynaecol* 17, 731-744 (2003)
157. Fagotti A, Ferrandina G, Fanfani F, Legge F, Lauriola L, Gessi M, Castelli P, Barbieri F, Minelli L, Scambia G. Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico pathological parameters. *Hum Reprod* 19, 393-397 (2004)
158. Hanna N, Bonifacio L, Reddy P, Hanna I, Weinberger B, Murphy S, Laskin D, Sharma S. IFN- γ -mediated inhibition of COX-2 expression in the

placenta from term and preterm labor pregnancies. *Am J Reprod Immunol* 51, 311-318 (2004)

159. van Kleffens M, Groffen C, Lindenberg-Kortleve DJ, van Neck JW, Gonzalez-Parra S, Dits N, Zwarthoff EC, Drop SL. The IGF system during fetal-placental development of the mouse. *Mol Cell Endocrinol* 140, 129-135 (1998)

160. Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. *Endocrine* 12, 121-136 (2000)

161. Nayak NR, Giudice LC. Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. *Placenta* 24, 281-296 (2003)

162. Oka Y, Rozek LM, Czech MP. Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. *J Biol Chem* 260, 9435-9442 (1985)

163. Czech MP. Signal transmission by the insulin-like growth factors. *Cell* 59, 235-238 (1989)

164. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. *Endocr Rev* 20, 761-787 (1999)

165. Tang XM, Rossi MJ, Masterson BJ, Chegini N. Insulin-like growth factor I (IGF-I), IGF-I receptors, and IGF binding proteins 1-4 in human uterine tissue: tissue localization and IGF-I action in endometrial stromal and myometrial smooth muscle cells *in vitro*. *Biol Reprod* 50, 1113-1125 (1994)

166. Henemyre C, Markoff E. Expression of insulin-like growth factor binding protein-4, insulin-like growth factor-I receptor, and insulin-like growth factor-I in the mouse uterus throughout the estrous cycle. *Mol Reprod Dev* 52, 350-359 (1999)

167. Talavera F, Reynolds RK, Roberts JA, Menon KM. Insulin-like growth factor I receptors in normal and neoplastic human endometrium. *Cancer Res* 50, 3019-3024 (1990)

168. Rutanen EM. Insulin-like growth factors in endometrial function. *Gynecol Endocrinol* 12, 399-406 (1998)

169. Giudice LC. Multifaceted roles for IGFBP-1 in human endometrium during implantation and pregnancy. *Ann N Y Acad Sci* 828, 146-56 (1997)

170. Markoff E, Henemyre C, Fellows J, Pennington E, Zeitler PS, Cedars MI. Localization of insulin-like growth factor binding protein-4 expression in the mouse uterus

during the peri-implantation period. *Biol Reprod* 53, 1103-1109 (1995)

171. Han VK, Carter AM. Spatial and temporal patterns of expression of messenger RNA for insulin-like growth factors and their binding proteins in the placenta of man and laboratory animals. *Placenta* 21, 289-305 (2000)

172. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type I IGF receptor (Igf1r). *Cell* 75, 59-72 (1993)

173. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. *Nature* 345, 78-80 (1990)

174. Constancia M, Hemberger M, Hughes J, Dean W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A, Sibley C, Reik W. Placental-specific IGF-II is a major modulator of placental and fetal growth. *Nature* 417, 945-948 (2002)

175. Curry TE Jr, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. *Endocr Rev* 24, 428-465 (2003)

176. Seval Y, Akkoyunlu G, Demir R, Asar M. Distribution patterns of matrix metalloproteinase (MMP)-2 and -9 and their inhibitors (TIMP-1 and TIMP-2) in the human decidua during early pregnancy. *Acta Histochem* 106, 353-362 (2004)

177. Librach CL, Feigenbaum SL, Bass KE, Cui TY, Verastas N, Sadovsky Y, Quigley JP, French DL, Fisher SJ. Interleukin-1 beta regulates human cytotrophoblast metalloproteinase activity and invasion *in vitro*. *J Biol Chem* 269, 17125-17131 (1994)

178. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. *J Clin Invest* 96, 2304-2310 (1995)

179. Roth I, Fisher SJ. IL-10 is an autocrine inhibitor of human placental cytotrophoblast MMP-9 production and invasion. *Dev Biol* 205, 194-204 (1999)

180. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. *Clin Cancer Res* 5, 189-196 (1999)

181. Wilson CL, Heppner KJ, Rudolph LA, Matrisian LM. The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. *Mol Biol Cell* 6, 851-869 (1995)

182. Rudolph-Owen LA, Hulboy DL, Wilson CL, Mudgett J, Matrisian LM. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. *Endocrinology* 138, 4902-4911 (1997)

183. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. *Cell* 93, 411-422 (1998)

184. Dubois B, Arnold B, Opdenakker G. Gelatinase B deficiency impairs reproduction. *J Clin Invest* 106, 627-628 (2000)

185. Soloway PD, Alexander CM, Werb Z, Jaenisch R. Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. *Oncogene* 13, 2307-2314 (1996)

186. Nothnick WB. Reduction in reproductive lifespan of tissue inhibitor of metalloproteinase 1 (TIMP-1)-deficient female mice. *Reproduction* 122, 923-927 (2001)

187. Riley P, Anson-Cartwright L, Cross JC. The Hand1 bHLH transcription factor is essential for placental and cardiac morphogenesis. *Nat Genet* 18, 271-275 (1998)

188. Scott IC, Anson-Cartwright L, Riley P, Reda D, Cross JC. The HAND1 basic helix-loop-helix transcription factor regulates trophoblast differentiation via multiple mechanisms. *Mol Cell Bio.* 20, 530-541 (2000)

189. Basyuk E, Cross JC, Corbin J, Nakayama H, Hunter P, Nait-Oumesmar B, Lazzarini RA. Murine Gcm1 gene is expressed in a subset of placental trophoblast cells. *Dev Dyn* 214, 303-311 (1999)

190. Anson-Cartwright L, Dawson K, Holmyard D, Fisher SJ, Lazzarini RA, Cross JC. The glial cells missing-1 protein is essential for branching morphogenesis in the chorioallantoic placenta. *Nat Genet* 25, 311-314 (2000)

191. Mellor AL, Chandler P, Lee GK, Johnson T, Keskin DB, Lee J, Munn DH. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. *J Reprod Immunol* Oct- 57, 143-150 (2002)

192. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science* 281, 1191-1193 (1998)

193. Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. *Nat Immunol* 2, 64-68 (2001)

194. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase expression

is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. *J Reprod Immunol* 61, 67-77 (2004)

Abbreviations: IDO: indoleamine-2,3-dioxygenase, IGF: insulin-like growth factor, IGFBP: insulin-like growth factor binding protein, IUGR: intrauterine growth restriction, LIF: leukemia inhibitory factor, MMP: matrix metalloproteinase, TIMP: Tissue inhibitor of metalloproteinase, uNK cell: uterine natural killer cell

Key Words: Cytokine, IGFBP-1, MMP, LIF, NK cell, Insulin growth factor, Gene knockout, blastocyst implantation, fetal development, Review

Send correspondence to: Dr Surendra Sharma, Departments of Pediatrics and Pathology, Women and Infants' Hospital of Rhode Island-Brown University, Providence, RI, 02905, Tel: 401-277-3618, Fax: 401-277-3617, E-mail: Ssharma@wihri.org

<http://www.bioscience.org/current/vol11.htm>